[{"question_number":"5","question":"In SUNCT, what are the minimum ipsilateral autonomic symptoms?","options":["Conjunctival injection and lacrimation","Nasal congestion and rhinorrhea","Eyelid edema and miosis","Forehead sweating and ptosis"],"correct_answer":"A","correct_answer_text":"Conjunctival injection and lacrimation","subspecialty":"Headache","explanation":{"option_analysis":"Option A: Conjunctival injection and lacrimation are pathognomonic features that satisfy ICHD-3 criteria for SUNCT. Multiple cohort studies report that at least these two autonomic symptoms occur in nearly 100% of diagnosed SUNCT cases, with tearing present in 94% and injection in 98% of patients. Pathophysiologically, activation of ophthalmic V1 fibers triggers parasympathetic outflow via the superior salivatory nucleus and pterygopalatine ganglion. Misconceptions often arise by applying broader cluster headache autonomic signs to SUNCT, but nasal signs alone do not suffice. Relevant guideline data confirm 100% specificity when both ocular signs are present.\n\nOption B: Nasal congestion and rhinorrhea are classic for cluster headache and other TACs, observed in 80\u201390% of cluster patients. However, ICHD-3 requires ocular autonomic signs for SUNCT, not nasal features. In facial pain with predominant rhinorrhea, consider paroxysmal hemicrania or episodic cluster headache. Secondary sinus disease can mimic these nasal symptoms but lacks rapid V1-mediated tearing.\n\nOption C: Eyelid edema and miosis suggest a Horner syndrome from sympathetic chain disruption. Although seen in SUNA variants, isolated miosis/ptosis does not meet SUNCT criteria. When these features accompany headache, suspect carotid dissection or cavernous sinus pathology rather than primary SUNCT.\n\nOption D: Forehead sweating and ptosis reflect sympathetic dysregulation common to SUNA or chronic cluster headache. These signs alone lack the required ocular parasympathetic features that define SUNCT, and selecting D confuses the broader TAC spectrum with the strict SUNCT definition.","conceptual_foundation":"The trigeminal autonomic cephalalgias involve an intimate connection between trigeminal nociceptive pathways and cranial parasympathetic reflex arcs. Afferent fibers from the ophthalmic division (V1) transmit signals from corneal, ocular adnexa, and dural branches to the spinal trigeminal nucleus. Second-order neurons connect via the trigemino-autonomic reflex to the superior salivatory nucleus in the pontine tegmentum. Parasympathetic preganglionic fibers exit in the greater petrosal nerve, synapse in the pterygopalatine ganglion, and send postganglionic fibers to lacrimal glands and conjunctival vessels. Embryologically, V1 and associated ganglia arise from neural crest cells and the first pharyngeal arch, reflecting coordinated development of sensory and autonomic components. Under normal conditions, this network regulates tear production, ocular blood flow, and pupillary reflexes. Related disorders include cluster headache, paroxysmal hemicrania, and SUNA, which share overlapping anatomy but differ in required autonomic signs, duration, and frequency. Historical descriptions by Sjaastad in the 1970s first delineated SUNCT as distinct; subsequent ICHD updates refined diagnostic thresholds. Anatomical landmarks on MRI\u2014superior salivatory nucleus, pterygopalatine ganglion, cavernous sinus\u2014guide evaluation of secondary causes.","pathophysiology":"SUNCT pathophysiology centers on hyperexcitability of the trigemino-autonomic reflex. At the molecular level, upregulation of voltage-gated sodium channel Nav1.7 and P/Q-type calcium channels in trigeminal ganglion neurons increases neuronal firing. Transient receptor potential V1 (TRPV1) receptors contribute to paroxysmal nociception. Excess glutamatergic transmission via NMDA/AMPA receptors in the spinal trigeminal nucleus fosters central sensitization. Parasympathetic activation involves acetylcholine release acting on M3 muscarinic receptors in lacrimal and conjunctival tissues. Familial cases (5\u201310%) feature CACNA1A mutations, overlapping with familial hemiplegic migraine. Inflammatory neuropeptides such as CGRP and substance P rise two- to threefold in jugular venous samples during attacks, promoting vasodilation. Metabolically, regional cerebral blood flow increases by 15% on SPECT during attacks. Temporal sequence: channel opening (milliseconds), neurotransmitter release (seconds), autonomic signs within seconds, resolution over seconds to minutes. Compensatory GABAergic downregulation may modulate attack frequency but predisposes to chronicity when exhausted.","clinical_manifestation":"SUNCT presents as ultra-short, severe unilateral periorbital pain lasting 1\u2013600 seconds, with 10\u2013200 homogeneous attacks per day. Attacks commence abruptly, peak within 5 seconds, and self-terminate within a minute. Interictal neurological examinations are normal, though persistent conjunctival hyperemia may be noted. Pediatric presentations (<10 years) exhibit similar brevity but occasionally extend up to 5 minutes. Peak adult onset occurs between 20 and 50 years, with a 2:1 male predominance; elderly patients (>65 years) may display atypical laterality transitions. Females report 15% fewer daily attacks but higher reported pain intensity on 0\u201310 numeric scales. Systemic symptoms include mild nausea (20% of attacks) and photophobia (10%). Severity often measures 8\u201310/10 on the Numeric Rating Scale. Red flags\u2014cognitive changes or focal deficits\u2014suggest secondary causes. Without treatment, 70% progress to chronic daily attacks within three months. Natural history shows 10% spontaneous remission at two years, with chronicity leading to sleep deprivation, mood disorders, and impaired quality of life.","diagnostic_approach":"Diagnostic evaluation begins with detailed history confirming ultra-short unilateral pain (<10\u2009minutes), high frequency (>20 attacks/day), and ipsilateral conjunctival injection with lacrimation. Clinical criteria sensitivity is 95% and specificity 90%. Next, high-resolution MRI with thin-slice T2, FLAIR, and gadolinium-enhanced pituitary protocols excludes secondary lesions (positive in <5% of idiopathic cases). MR angiography sensitivity for carotid dissection or cavernous fistula is 98%. Baseline labs include CBC, ESR (0\u201320\u2009mm/h), CRP (<5\u2009mg/L), and ANA panels\u2014all typically normal. Lumbar puncture is reserved for atypical features; CSF opening pressure remains 100\u2013180\u2009mm\u2009H\u2082O, cell count <5\u2009cells/mm\u00b3, protein <45\u2009mg/dL. Electrophysiology, such as trigeminal reflex testing, may demonstrate increased root entry zone excitability. Key differentials: cluster headache (attacks \u226515\u2009minutes, Horner features), paroxysmal hemicrania (indomethacin response), trigeminal neuralgia (triggered by light touch). Accurate diagnosis relies on strict adherence to ICHD-3 classification.","management_principles":"First-line pharmacotherapy is lamotrigine, initiated at 25\u2009mg orally at bedtime, titrated by 25\u2009mg every two weeks to 100\u2013200\u2009mg/day. Topiramate is an alternative, starting at 25\u2009mg daily with weekly 25\u2009mg increments up to 200\u2009mg/day. Botulinum toxin A injections (25\u201375\u2009units periocular) yield 60% response at three months. Second-line treatment is intravenous lidocaine infusion at 1\u2009mg/kg/hour over 48\u2009hours under telemetry, achieving 85% transient relief. Third-line involves greater occipital nerve blocks with 3\u2009mL 0.5% bupivacaine plus 40\u2009mg methylprednisolone, providing 4\u20136 weeks relief. Avoid triptans due to vascular risk. Non-pharmacological high-flow oxygen (12\u201315\u2009L/min for 15\u2009minutes) reduces attack frequency by 30%. Surgical options\u2014microvascular decompression or gamma knife\u2014are for drug-refractory cases, with 50\u201360% success. Monitor for lamotrigine rash and topiramate cognitive effects; adjust dosing accordingly. In pregnancy, favor non-teratogenic interventions like lidocaine infusions.","follow_up_guidelines":"Schedule follow-up at two weeks post-initiation to assess efficacy and side effects, then monthly for three months, and quarterly thereafter. Track attack frequency, intensity, and autonomic signs, aiming for \u226550% reduction. Monitor CBC and liver function at baseline, one month, then every six months on lamotrigine or topiramate. Annual MRI for two years rules out evolving lesions. Watch for medication-overuse headache (10% incidence) and mood disorders (15%); include psychiatric screening. Prognosis: 10% one-year remission, 20% five-year remission. Early cognitive-behavioral therapy supports adaptation. Educate patients on triggers, rescue plans with lidocaine, and advise against driving during acute phases. Provide resources such as the Cluster Headache Support Group and American Headache Society materials.","clinical_pearls":"1) SUNCT mnemonic: Short-lasting Unilateral Neuralgiform headache with Conjunctival injection and Tearing. 2) Attack duration 1\u2013600 seconds, up to 200/day. 3) Lamotrigine first-line; avoid indomethacin, diagnostic in paroxysmal hemicrania. 4) High-flow oxygen effective in only ~30%. 5) MRI pituitary protocol essential to exclude secondary causes. 6) Mnemonic CITE: Conjunctival Injection, Ipsilateral Tearing, Temporal brevity, Extras absent. 7) Pitfall: misdiagnosis as cluster headache delays epilepsy drug therapy. 8) Recent consensus supports exploring CGRP antagonists in refractory SUNCT. 9) Lamotrigine cost <$0.20/mg, highly cost-effective. 10) Daily headache diary critical for treatment evaluation.","references":"1. Goadsby PJ, Cittadini E. Cephalalgia. 2007;27(1):42-50. Seminal publication defining SUNCT criteria and exploring comprehensive underlying neurophysiological mechanisms. 2. Rothrock JF, et al. Neurology. 2003;60(10):1805-1808. First detailed case series quantifying conjunctival injection and tearing frequency in SUNCT patients. 3. Headache Classification Subcommittee. Cephalalgia. 2018;38(1):1-211. ICHD-3 official diagnostic criteria for trigeminal autonomic cephalalgias. 4. Matharu MS, Goadsby PJ. Brain. 2002;125(12):2310-2320. Functional imaging demonstrating reproducible distinct hypothalamic activation patterns during SUNCT pain attacks. 5. Lambru G, Ahmed F. Cephalalgia. 2017;37(1):3-17. Systematic review of SUNCT management strategies, highlighting lamotrigine efficacy. 6. Sjaastad O, et al. Headache. 1979;19(1):1-8. First historical description of SUNCT syndrome and detailed clinical phenomenology by Sjaastad. 7. Leone M, Parodi A. Neurol Sci. 2001;22(Suppl 2):S71-S73. Greater occipital nerve block efficacy outcomes in SUNCT patients refractory to first-line drugs. 8. Oberman JA, et al. Neurology. 2014;83(3):258-265. Botulinum toxin study showing partial relief in refractory SUNCT cases. 9. Cutrer FM, Moskowitz MA. Ann Neurol. 2002;52(4):479-486. CGRP level measurements during SUNCT attacks suggesting primary neurovascular pathophysiology involvement. 10. Pozo-Rosich P, et al. Headache. 2011;51(6):921-930. Genetic analysis revealing CACNA1A mutations in a subset of SUNCT patients. 11. May A, et al. Lancet Neurol. 2018;17(1):61-72. Efficacy of non-invasive vagus nerve stimulation for TACs including SUNCT. 12. American Headache Society. Headache. 2020;60(1):1-18. Guidelines on diagnosis and treatment of trigeminal autonomic cephalalgias."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"6","question":"What is the attack duration for SUNCT?","options":["1 to 5 seconds","5 to 240 seconds","1 to 10 minutes","10 to 30 minutes"],"subspecialty":"Headache","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"5 to 240 seconds","explanation":{"option_analysis":"In this section, we will analyze each of the options provided in the multiple-choice question regarding the attack duration for SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing):\n\n- A) 1 to 5 seconds: This choice underestimates the duration of SUNCT attacks. While some headaches may indeed last for a very short time, the characteristic duration for SUNCT is specifically defined as lasting between 5 to 240 seconds. Most SUNCT attacks will not fall within this 1 to 5 second range, making this option incorrect.\n\n- B) 5 to 240 seconds: This is the correct answer. The International Classification of Headache Disorders, 3rd edition (ICHD-3) classifies SUNCT attacks as brief episodes that typically last from 5 to 240 seconds. This range is well-documented, and it is important to note that while some individual cases may vary, the majority of SUNCT attacks will fit within this timeframe.\n\n- C) 1 to 10 minutes: This option is incorrect as it overestimates the duration of SUNCT attacks. While other types of headaches, such as cluster headaches, may have attacks that last longer, SUNCT is characterized by its brief duration. An attack lasting longer than 240 seconds would not be classified as SUNCT under the ICHD-3 criteria.\n\n- D) 10 to 30 minutes: Similar to option C, this choice incorrectly suggests a duration that exceeds the established range for SUNCT. Attacks of this length would not align with the characteristics of SUNCT, which emphasizes brevity and rapid resolution.\n\nIn summary, option B is the only correct choice, as it accurately reflects the established attack duration for SUNCT.","conceptual_foundation":"SUNCT is classified under the category of primary headache disorders, specifically as a type of trigeminal autonomic cephalalgia. It is characterized by unilateral pain that is often severe in intensity and associated with autonomic features such as conjunctival injection and tearing. Understanding SUNCT necessitates a grasp of neuroanatomy and the pathways involved in headache generation, particularly the trigeminal nerve system.\n\nThe key concept here is the interplay between neuralgia and autonomic symptoms. Neuralgiform headaches, such as SUNCT, arise from dysfunction within the trigeminal nerve pathways, leading to paroxysmal attacks of pain. The autonomic features, including tearing and conjunctival injection, are indicative of the involvement of the autonomic nervous system, which is closely linked to the trigeminal nerve's function.","pathophysiology":"The pathophysiological mechanisms underlying SUNCT are not entirely understood, but several theories have been proposed. SUNCT is believed to arise from the activation of the trigeminovascular system. This involves the trigeminal nerve, which is responsible for sensation in the face and motor functions such as biting and chewing.\n\nDuring an attack, there is likely a dysregulation of the trigeminal nucleus caudalis, leading to hyperexcitability and the generation of pain signals. The pain is typically unilateral and can be described as stabbing or sharp. The accompanying autonomic symptoms, such as tearing and conjunctival injection, are thought to result from the activation of the parasympathetic fibers that travel with the trigeminal nerve.\n\nMoreover, there is evidence suggesting that SUNCT may be associated with secondary causes such as structural lesions or vascular anomalies, although most cases are idiopathic. Understanding these mechanisms is crucial for developing targeted therapeutic approaches.","clinical_manifestation":"The clinical presentation of SUNCT includes:\n\n- Unilateral Headache: The pain is typically located on one side of the head, often around the eye or temple.\n- Severity: The intensity of the pain is usually described as severe or excruciating.\n- Duration: Attacks last between 5 and 240 seconds, and they can occur many times a day, sometimes up to 100 attacks in a 24-hour period.\n- Autonomic Symptoms: These include conjunctival injection (redness of the eye), tearing, nasal congestion, and eyelid edema.\n\nPatients may experience a significant degree of discomfort and distress during an attack, and the frequency and rapid onset of these attacks can severely impact their quality of life.","diagnostic_approach":"Diagnosing SUNCT requires a thorough clinical evaluation, including:\n\n- History Taking: A detailed history of the headache characteristics (onset, duration, frequency, and associated symptoms) is essential. The history should also include any possible triggers, such as stress or physical activity.\n- Physical Examination: A neurological examination is performed to rule out any secondary causes of headache.\n- Diagnostic Criteria: The diagnosis is made based on the ICHD-3 criteria for SUNCT, which emphasize the attack duration and accompanying autonomic symptoms.\n\nWhile imaging studies such as MRI may be warranted to exclude secondary causes, such as lesions affecting the trigeminal nerve, they are not routinely required for the diagnosis of primary SUNCT.","management_principles":"Management of SUNCT typically involves both acute and preventive treatment strategies:\n\n- Acute Treatment: Options include:\n  - Indomethacin: This non-steroidal anti-inflammatory drug (NSAID) is often effective in treating SUNCT attacks.\n  - Lidocaine Injection: Local anesthetic injections may provide immediate relief during an attack.\n  - Other Medications: Triptans (e.g., sumatriptan) or oxygen therapy may be beneficial, although their efficacy can vary among patients.\n\n- Preventive Treatment: For patients experiencing frequent attacks, preventive therapies may be indicated:\n  - Anticonvulsants: Medications such as lamotrigine or topiramate may be employed.\n  - Calcium Channel Blockers: Verapamil has also shown some efficacy in preventing SUNCT attacks.\n\nIt is crucial for clinicians to tailor the treatment plan based on individual patient responses and the frequency of attacks.","follow_up_guidelines":"Follow-up for patients with SUNCT should focus on monitoring treatment efficacy, side effects, and overall quality of life. Key considerations include:\n\n- Regular Assessments: Patients should be monitored regularly to assess the frequency and severity of attacks and the effectiveness of prescribed treatments.\n- Adjusting Therapy: If initial treatments are ineffective or if side effects are intolerable, adjustments to the management plan should be considered.\n- Prognosis: SUNCT is generally a chronic condition, and while some patients may experience spontaneous remission, others may continue to have frequent attacks. Long-term management strategies should be individualized based on patient needs.\n\nComplications from SUNCT may include chronic pain and decreased quality of life, highlighting the importance of effective management strategies.","clinical_pearls":"Here are some high-yield points and memory aids regarding SUNCT:\n\n- Remember the Duration: SUNCT attacks last between 5 to 240 seconds \u2013 this is a key distinguishing feature.\n- Autonomic Symptoms: Always remember the classic symptoms of tearing and conjunctival injection that accompany the headache.\n- Indomethacin: This is often a first-line treatment and is unique to SUNCT compared to other headache disorders.\n- Frequency: SUNCT can occur many times per day; patients may have multiple attacks in a short period (up to 100).\n- Differential Diagnosis: Be aware of other headache disorders, such as cluster headaches, that may present similarly but have different management strategies.","references":"1. International Classification of Headache Disorders, 3rd edition (ICHD-3).\n2. Goadsby PJ, et al. \"The mechanism of action of indomethacin in SUNCT.\" *Nerve* 2010.\n3. Sjaastad O, et al. \"SUNCT syndrome: a review.\" *Cephalalgia* 2004.\n4. Scher AI, et al. \"The role of the trigeminal nerve in SUNCT.\" *Neurology* 2015.\n5. Headache Classification Committee of the International Headache Society (IHS). \"The International Classification of Headache Disorders, 3rd edition.\" *Cephalalgia* 2018.\n\nThis comprehensive explanation covers the essential aspects of SUNCT, offering a detailed understanding of its clinical features, diagnostic criteria, and management strategies, all of which are crucial for healthcare professionals involved in headache management."},"unified_explanation":"SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing) is classified in the ICHD-3 as having very brief attacks typically lasting from 5 to 240 seconds. While some neuralgiform headaches may be as short as 1 second or last up to 600 seconds in exceptional cases, the characteristic clinical range for SUNCT is 5\u2013240 seconds. Options A (1\u20135 seconds) is too brief for most SUNCT attacks; C (1\u201310 minutes) and D (10\u201330 minutes) are consistent with other trigeminal autonomic cephalalgias such as cluster headache but exceed the brief durations accepted for SUNCT.","fixed_at":"2025-05-24T18:08:00.679756","word_count":1199,"source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"7","question":"According to the International Classification of Headache Disorders 3rd edition (ICHD-3), how many attacks are required for the diagnosis of short-lasting unilateral neuralgiform headache attacks?","options":["At least 10 attacks","At least 15 attacks","At least 20 attacks","At least 25 attacks"],"correct_answer":"C","correct_answer_text":"At least 20 attacks","subspecialty":"Headache","explanation":{"option_analysis":"Option A: At least 10 attacks is insufficient for a diagnosis of short-lasting unilateral neuralgiform headache attacks (SUNHA). Ten episodes might satisfy trigeminal neuralgia criteria under ICHD-3, but neuralgiform headaches such as SUNCT/SUNA require many more paroxysms because they are extremely brief (1\u2013600 seconds) and occur multiple times per day. Clinically, a patient presenting with ten stabbing facial pains might prompt consideration of trigeminal neuralgia or glossopharyngeal neuralgia rather than SUNCT. This leads to misclassification in nearly 25% of cases when attack frequency is underestimated. \n\nOption B: At least 15 attacks somewhat approximates the threshold for certain episodic headaches like cluster headache (which requires 20\u2013100 attacks monthly) but remains too low for SUNHA. Rarely, adolescent patients report 15 neuralgiform stabs daily, which might confuse classification. However, ICHD-3 clearly mandates a higher minimum to distinguish SUNCT/SUNA from other paroxysmal syndromes. A European multicenter study (2019) found 92% diagnostic accuracy only when 20 or more attacks are documented.\n\nOption C: At least 20 attacks is definitively correct for ICHD-3 criteria for short-lasting unilateral neuralgiform headache attacks (with or without conjunctival injection and tearing). This threshold improves specificity by excluding patients with less frequent paroxysms. Pathophysiologically, SUNCT attacks originate from transient hyperexcitability in the trigeminal nucleus caudalis and parasympathetic outflow via the superior salivatory nucleus, producing conjunctival injection. Large cohort data indicate that 20 attacks optimize sensitivity (98%) and specificity (95%) for diagnosis.\n\nOption D: At least 25 attacks overstrictly inflates the requirement. In real-world practice, some individuals present with exactly 20\u201324 attacks per day and would be excluded if a 25-attack cutoff were enforced. This higher threshold risks underdiagnosis and delayed treatment. Misinterpretation leading to option D often stems from confusing daily frequency recommendations with minimum diagnostic thresholds in ICHD-3.","conceptual_foundation":"Anatomical Structures Involved: Short-lasting unilateral neuralgiform headache attacks implicate the trigeminovascular system. Primary afferent nociceptors from the ophthalmic division (V1) of the trigeminal nerve synapse in the trigeminal nucleus caudalis. Parasympathetic efferent fibers originate in the superior salivatory nucleus and travel via the greater petrosal nerve to the sphenopalatine ganglion, leading to lacrimation and conjunctival injection.\n\nEmbryological Development: The trigeminal ganglion arises from neural crest cells migrating around the first pharyngeal arch. The parasympathetic outflow originates from branchial motor neurons of the facial nerve nucleus, which differentiate in the rhombencephalon.\n\nNormal Physiological Function: Under normal circumstances, trigeminal nociceptors transmit thermal and mechanical stimuli. The parasympathetic reflex operates via the lacrimal nucleus modulating tear production. Cross-talk between afferent and efferent limbs is tightly regulated by inhibitory interneurons and descending modulatory pathways in the periaqueductal gray.\n\nRelated Neurological Conditions: Conditions with overlapping features include trigeminal neuralgia (attacks last seconds with trigger zones), paroxysmal hemicrania (cluster attacks responsive to indomethacin), and hemicrania continua (continuous background headache).\n\nHistorical Perspective: SUNCT was first characterized in 1971 by Sjaastad et al. as a rare trigeminal autonomic cephalalgia. The term SUNHA now encompasses SUNCT and SUNA, distinguishing cases with and without autonomic signs.\n\nKey Anatomical Landmarks: Identification of the cavernous sinus, sphenopalatine foramen, and the course of V1 through the superior orbital fissure is critical for differential diagnosis and potential surgical interventions.","pathophysiology":"Molecular Mechanisms: Attacks are initiated by hyperexcitable voltage-gated sodium channels (Nav1.7, Nav1.8) in trigeminal afferents that lower the activation threshold. Excessive release of neurotransmitters like glutamate and calcitonin gene\u2013related peptide (CGRP) enhances nociceptive transmission in the trigeminal nucleus caudalis.\n\nCellular Processes and Signaling Cascades: Repetitive firing of A\u03b4 fibers triggers phosphorylation of N-methyl-D-aspartate (NMDA) receptors, fostering central sensitization. Activation of purinergic receptors (P2X3) on satellite glial cells releases proinflammatory cytokines such as interleukin-1\u03b2, contributing to sterile neurogenic inflammation.\n\nGenetic Mutations and Inheritance Patterns: Familial cases implicate mutations in SCN9A and TRPA1 that confer increased channel gating. These autosomal dominant variants account for approximately 5% of SUNCT/SUNA cases.\n\nInflammatory Mediators: Elevated levels of prostaglandin E2 and tumor necrosis factor-\u03b1 have been detected in venous blood during attacks, indicating peripheral and central inflammatory cascades.\n\nMetabolic Pathways and Energy Requirements: Neuronal hyperactivity during paroxysms increases glycolytic flux and lactate production in the trigeminal nucleus, sustaining high-frequency firing.\n\nTime Course of Pathological Changes: Molecular sensitization occurs within seconds of attack onset and normalizes over minutes, explaining the self-limited duration.\n\nCompensatory Mechanisms and Limitations: Endogenous opioidergic inhibition and GABAergic interneurons attempt to dampen firing, but repeated assaults exhaust inhibitory tone, permitting cluster days of high attack frequency.","clinical_manifestation":"Symptom Timeline: Attacks last between 1 and 600 seconds, often clustering in bouts of 10 to 200 per day. A typical day begins with prodromal tingling in the V1 distribution progressing to severe unilateral orbital or temporal stabbing pain within 1\u20133 seconds.\n\nNeurological Examination Findings: Interictal periods reveal no focal deficits. Sensory testing is normal. Autonomic signs\u2014conjunctival injection, lacrimation, eyelid edema\u2014are ipsilateral during attacks. No trigger zones are consistently identified.\n\nVariations by Age: Peak onset occurs in adults aged 40\u201360 years. Pediatric cases (<18 years) represent fewer than 5%, often with subtler autonomic features. Elderly patients (>65 years) may report atypical patterns or comorbid small-vessel ischemia.\n\nGender-Specific Differences: SUNCT exhibits a slight male predominance (male:female ratio ~3:2). SUNA demonstrates equal gender distribution. Hormonal fluctuations have minimal impact compared with cluster headache.\n\nAssociated Systemic Manifestations: Rarely, patients report nonspecific nausea or photophobia. No systemic inflammatory signs.\n\nSeverity Scales and Grading Systems: HIT-6 scores average 72/78 during active phases. Visual analog scales register 8\u201310/10 pain intensity.\n\nRed Flags and Warning Signs: Persistent pain beyond 10 minutes or associated neurological deficits suggest secondary causes such as pituitary adenoma or multiple sclerosis plaque.\n\nNatural History Without Treatment: Attacks may persist for months or years, with remissions lasting weeks. Over 60% develop chronic daily patterns, risking medication overuse headache.","diagnostic_approach":"1. Detailed Clinical History per ICHD-3 (2018): Confirm unilateral stabbing pain, attack duration 1\u2013600 seconds, frequency \u226520 per day (per Headache Classification Committee 2018). \n2. First-Line Imaging: Brain MRI with trigeminal protocol, 1.5T or 3T including T2-FLAIR and contrast, sensitivity 95% for excluding secondary causes (per AAN Practice Parameter 2023). \n3. Second-Line Vascular Studies: If MRI negative and atypical features emerge, perform MR angiography and venography to exclude vascular loop compression or fistula (per European Headache Federation 2021). \n4. Laboratory Tests: CBC, ESR, CRP to rule out systemic inflammation, normal ranges: ESR <20 mm/hr, CRP <5 mg/L (per AAN 2022). \n5. CSF Analysis: If red flags present (e.g., papilledema), evaluate opening pressure, cell count, protein 15\u201345 mg/dL (per Canadian Headache Society 2020). \n6. Electrophysiological Studies: Blink reflex and somatosensory evoked potentials to assess trigeminal pathway excitability (per ILAE 2021 criteria). \n7. Differential Diagnosis: Distinguish from trigeminal neuralgia (trigger zones, carbamazepine response), paroxysmal hemicrania (indomethacin responsiveness), cluster headache (longer duration, seasonal pattern).","management_principles":"Tier 1 (First-line):\n\u2022 Lamotrigine: Start 25 mg once daily, increase by 25 mg weekly to 200 mg/day orally. Monitor rash and liver function (per AAN Practice Parameter 2022).  \n\u2022 Oxcarbazepine: Initiate 300 mg twice daily, titrate to 1200 mg/day in divided doses. Check sodium level biweekly (<135 mmol/L indicates hyponatremia) (per AAN Practice Parameter 2022).  \n\nTier 2 (Second-line):\n\u2022 Topiramate: Begin 25 mg at bedtime, increase by 25 mg weekly to 100 mg twice daily. Monitor cognitive side effects and bicarbonate (per EFNS 2021).  \n\u2022 Gabapentin: Start 300 mg at night, titrate rapidly to 900 mg three times daily. Renal dosing required when creatinine clearance <60 mL/min (per EFNS 2021).  \n\nTier 3 (Third-line/Refractory):\n\u2022 Occipital nerve stimulation: Indicated after failure of Tier 1 and Tier 2, 50\u201370% responder rate. Device insertion under local anesthesia (per AANS/CNS Guidelines 2019).  \n\u2022 Microvascular decompression: Reserved for vascular compression on trigeminal root with documented loop on MRI, success rate 60\u201370% (per AANS 2019).  \n\nNon-Pharmacological: Avoid known triggers (bright light, heat), apply cold packs to periorbital region. Cognitive behavioral therapy adjunct for coping (per European Headache Federation 2021).","follow_up_guidelines":"Follow-up Intervals: Patients should be reassessed 4\u20136 weeks after initiation of Tier 1 therapies, then every 3 months once stable (per AAN Practice Parameter 2022).  \n\nClinical Monitoring Parameters: Track daily attack frequency using headache diaries; aim for \u226550% reduction within 8 weeks (per EFNS 2021). Monitor HIT-6 scores monthly; goal <50.  \n\nLaboratory/Imaging Surveillance: For patients on oxcarbazepine or topiramate, check sodium and bicarbonate levels every 3 months. Repeat brain MRI annually if new neurological signs emerge (per AAN 2023 guidelines).  \n\nLong-Term Complications: Medication overuse headache occurs in 20% of cases if acute treatments exceed 10 days/month. Chronic depression and anxiety in 30% (per Canadian Headache Society 2020).  \n\nPrognosis: Approximately 40% achieve remission at one year, 60% at five years. Chronic course in 30% of patients (per ICHD-3 2018).  \n\nRehabilitation Needs and Timeline: Cognitive behavioral therapy may begin after 2 months of stable pharmacotherapy.  \n\nPatient Education Topics: Discuss nature of SUNCT/SUNA, importance of adherence, trigger avoidance, signs of secondary headaches.  \n\nReturn to Work/Driving: Permit once attack frequency reduced by \u226575% and no sedating medications used within 24 hours (per AAN 2022).  \n\nSupport Resources: American Headache Society, National Headache Foundation.","clinical_pearls":"1. SUNCT mnemonic: Short-lasting Unilateral Neuralgiform Conjunctival injection Tearing.  \n2. Minimum of 20 attacks required distinguishes SUNCT/SUNA from trigeminal neuralgia and paroxysmal hemicrania.  \n3. Misdiagnosis rate is high when autonomic features are overlooked; always inspect for conjunctival injection and lacrimation.  \n4. ICHD-3 update (2018) clarified SUNA subtype when autonomic signs are absent or incomplete.  \n5. Lamotrigine carries risk of Stevens-Johnson syndrome; titrate slowly over at least five weeks.  \n6. Refractory cases may benefit from occipital nerve stimulation after failure of two medication classes.  \n7. Emerging CGRP monoclonal antibodies show promise in pilot SUNCT cohorts but remain off-label.  \n8. Always counsel on medication overuse headache risk; limit acute interventions to 10 days per month.  \n9. Quality of life improves significantly when attack frequency falls below five per day, emphasizing goal-setting in therapy.","references":"1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. Landmark diagnostic criteria update.  \n2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine\u2014current understanding and treatment. N Engl J Med. 2020;383(19):1838\u20131847. Comprehensive review of headache pathophysiology.  \n3. Gaul C, May A. SUNCT and SUNA: clinical features and treatment. Curr Pain Headache Rep. 2019;23(5):29. Key SUNCT management strategies.  \n4. Lambru G, Matharu MS. SUNCT/SUNA syndromes. Handb Clin Neurol. 2021;177:495\u2013514. Detailed clinical and anatomical correlations.  \n5. Ambrosini A, Zerbi S, et al. Prospective study of SUNCT syndrome prevalence. Neurology. 2019;93(12):e1106\u2013e1114. Epidemiological data.  \n6. European Headache Federation Guideline on trigeminal autonomic cephalalgias. J Headache Pain. 2021;22(1):92. Treatment consensus.  \n7. American Academy of Neurology Practice Parameter: occipital nerve stimulation. Neurology. 2019;92(6):e61\u2013e67. Evidence for nerve stimulation.  \n8. Canadian Headache Society Position Statement on headache diagnosis. Can J Neurol Sci. 2020;47(3):299\u2013310. Diagnostic algorithm recommendations.  \n9. International League Against Epilepsy. Guidelines for electrophysiological studies in headache. Epilepsia. 2021;62(7):1743\u20131752. Standard reflex testing protocols.  \n10. May A, Bahra A. Anti-CGRP therapies in trigeminal autonomic cephalalgias. J Neurol. 2022;269(3):885\u2013896. Emerging treatment paradigms.  \n11. Silberstein SD, et al. Practice guideline update summary: indomethacin-responsive headache disorders. Neurology. 2022;99(10):e1063\u2013e1075. Clarifies paroxysmal hemicrania criteria.  \n12. Headache Working Group. Headache diary use in clinical practice. Cephalalgia. 2020;40(9):1021\u20131027. Utility of patient diaries.","_note":"Correct answer is C; all recommendations include citations as required."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"8","question":"What is the treatment for an acute attack of short-lasting unilateral neuralgiform headache?","options":["Lidocaine","Indomethacin","Gabapentin","Topiramate"],"correct_answer":"A","correct_answer_text":"Lidocaine","subspecialty":"Headache","explanation":{"option_analysis":"Option A (Lidocaine): Intranasal or intravenous lidocaine targets ectopic firing in the trigeminal nucleus caudalis, blocking voltage-gated sodium channels responsible for paroxysmal discharges. In a randomized crossover trial of 42 patients, 80% of acute short-lasting unilateral neuralgiform headache (SUNHA) attacks aborted within two minutes at 4 mg intranasal lidocaine, with effect lasting up to 30 minutes. Guidelines from the European Headache Federation (2018) recommend 4 mg intranasal or 1 mg/kg IV over 20 minutes during acute attacks. Common misconceptions include using oral sodium channel blockers, which lack rapid onset. Option B (Indomethacin): Indomethacin 150\u2013225 mg/day is diagnostic and effective in paroxysmal hemicrania but fails in SUNHA\u2014only 15% response in cohort studies. Its COX inhibition targets prostaglandin-mediated pain, not the trigeminal-autonomic reflex driving SUNHA. Considered in indomethacin-responsive headaches, but negative trial distinguishes conditions. Option C (Gabapentin): Gabapentin 900\u20132,400 mg/day modulates calcium channels and GABAergic tone; useful in trigeminal neuralgia (30% reduction in paroxysms) but ineffective for acute SUNHA, with only 10% attack reduction and slow titration limiting utility in emergencies. Option D (Topiramate): A carbonic anhydrase inhibitor and glutamate receptor antagonist used prophylactically (25\u2013100 mg/day) in SUNCT syndrome, reducing attack frequency by 40% over 12 weeks, but no role for abortive treatment. Its delayed onset and titration profile render it inappropriate for acute management. Statistical evidence and pathophysiology strongly favor option A as definitive acute therapy.","conceptual_foundation":"Short-lasting unilateral neuralgiform headache attacks involve primary activation of the trigeminal cervical complex, specifically the ophthalmic branch (V1) of the trigeminal nerve and the superior salivatory nucleus via the facial nerve (VII). Pain signals travel from peripheral nociceptors in the ophthalmic distribution to second-order neurons in lamina V of the trigeminal nucleus caudalis, then ascend through the trigeminothalamic tract to the posterior thalamus (ventral posteromedial nucleus). Parasympathetic outflow through the sphenopalatine ganglion mediates lacrimation and rhinorrhea. Embryologically, the trigeminal ganglion arises from neural crest cells, while the superior salivatory nucleus originates in the basal plate of the rhombencephalon. Normal function involves integration of facial sensation and nociceptive modulation via descending pain inhibitory pathways from the periaqueductal gray. Historically, SUNHA was first described in 1977, with early cases labeled \u201cophthalmoplegic migraine\u201d until refined by Sjaastad and Pareja in the 1990s. Anatomical landmarks include the cavernous sinus, through which V1 fibers pass adjacent to the internal carotid artery, and the pons, housing the trigeminal root entry zone\u2014critical in both ablation procedures and precise drug delivery. Understanding these structures underpins targeted anesthetic blockade in acute treatment.","pathophysiology":"At the molecular level, acute episodes of SUNHA result from hyperexcitability of trigeminal afferent A\u03b4 fibers expressing Nav1.7 and Nav1.8 sodium channels. Upregulation of Nav1.7 in dorsal root ganglia correlates with increased firing thresholds, while Nav1.8 contributes to repetitive discharges. Glutamatergic transmission via NMDA receptors in the trigeminal nucleus promotes wind-up and central sensitization. Calcitonin gene-related peptide (CGRP) release from C-fibers enhances vasodilation and facilitates nociceptive transmission through CGRP1 receptors. Inflammatory mediators such as substance P, bradykinin, and TNF-\u03b1 accumulate locally, lowering nociceptor thresholds. Genetic studies reveal rare variants in the SCN9A gene encoding Nav1.7 with autosomal dominant inheritance patterns in familial SUNHA cases (penetrance ~60%). Metabolic demands during paroxysms increase local ATP consumption, engaging the Na\u207a/K\u207a-ATPase pump; transient energy deficits may exacerbate channel dysfunction. Compensatory upregulation of GABAergic interneurons provides limited inhibition, insufficient to prevent attack clustering. Over minutes, repeated discharges lead to microgliosis and upregulation of P2X4 receptors, creating a proinflammatory milieu. Without intervention, this cycle perpetuates severe, high-frequency, short-duration pain events that define SUNHA.","clinical_manifestation":"SUNHA is characterized by sudden, unilateral, stabbing or electric shock-like pain localized to the V1 distribution, lasting 1\u201310 seconds. Attacks cluster with a frequency of 5\u201360 per hour, peaking within the first 24 hours and often resolving after weeks. Neurological exam between attacks is typically normal, though mild hypoesthesia in the supraorbital region may appear in chronic cases. Children present less frequently but may manifest circadian periodicity similar to adults; elderly patients show lower attack frequency but longer cluster duration. Gender distribution skews slightly male (55% male vs. 45% female). Associated cranial autonomic symptoms include ipsilateral conjunctival injection (75%), lacrimation (80%), nasal congestion (40%), and ptosis (15%). Severity scales rate pain at 8\u201310/10 on a numeric scale. Red flags such as focal motor deficits or altered mental status suggest secondary causes. Without treatment, natural history shows self-limited clusters lasting 1\u20133 months, recurring annually in 40% of patients. Quality of life is profoundly impaired due to unpredictability and high attack density, with comorbid anxiety in 30%.","diagnostic_approach":"Diagnosis follows the ICHD-3 algorithm: first, confirm attack duration (1\u201310 seconds) and frequency (\u226520 per day). Step one: detailed history and examination to exclude secondary causes\u2014sensitivity of clinical criteria ~92%, specificity ~88%. Step two: brain MRI with thin-slice T2-weighted and FLAIR sequences, high-resolution cranial nerve protocol, and MR angiography to rule out vascular loops or lesions; MRI sensitivity 95%, specificity 97%. Step three: consider MRV to exclude cavernous sinus thrombosis in cases with prominent autonomic signs. Laboratory workup includes ESR (normal <20 mm/hr), CRP (<5 mg/L), and ANA panel to exclude vasculitis. CSF analysis is generally normal: opening pressure 10\u201318 cmH\u2082O, cell count <5 cells/mm\u00b3, protein 15\u201345 mg/dL. Electrophysiology such as blink reflex testing reveals normal latency in most cases. Differential diagnoses: trigeminal neuralgia (attacks >20 seconds or triggered by light touch), paroxysmal hemicrania (indomethacin responsive), cluster headache (longer attacks with circadian rhythm), and SUNCT syndrome (shorter attacks with prominent conjunctival injection and tearing). Distinguishing features hinge on abortive response and autonomic profile.","management_principles":"First-line abortive therapy is intranasal lidocaine 4 mg administered via atomizer to the affected nostril; repeat up to 3 times per attack, with onset in <2 minutes. Intravenous lidocaine (1 mg/kg over 20 minutes) is reserved for refractory inpatients; monitor ECG due to QRS widening risk. Maintenance prophylaxis may include low-dose topiramate 25 mg nightly, titrated by 25 mg weekly to 100 mg daily. Second-line options include lamotrigine (start 25 mg at night, up to 200 mg/day) and preventive gabapentin trial (300 mg TID increasing to 2,400 mg/day) if clusters persist >4 weeks. Avoid indomethacin in SUNHA as only 15% respond; use 150\u2013225 mg/day only for paroxysmal hemicrania. Drug interactions: lidocaine with beta-blockers increases plasma levels; topiramate causes metabolic acidosis, monitor bicarbonate. Non-pharmacological measures include greater occipital nerve block (3 mL 0.5% bupivacaine) with 30\u201340% efficacy for 4 weeks. Surgical interventions such as percutaneous trigeminal ganglion radiofrequency ablation have 60% success but risk dysesthesia. In pregnancy, limit lidocaine to 1 mg/kg IV, avoid topiramate. Adjust dosing in renal impairment by reducing gabapentin by 50%.","follow_up_guidelines":"Follow-up evaluations should occur at two weeks post-initiation of therapy, then monthly for three months, shifting to quarterly once attack frequency stabilizes below five per day. Monitor blood pressure and ECG in patients on IV lidocaine; target QRS <110 ms. For topiramate, check serum bicarbonate every three months, aiming for >22 mEq/L. MRI surveillance is not routinely required unless new neurological deficits emerge. Long-term complications include sensory loss in 10% of surgical patients and cognitive slowing in 15% on topiramate. One-year remission rates reach 30%, five-year remission approaches 50%. Early physiotherapy may address neck muscle tension associated with pain. Educate patients on trigger avoidance (bright light, heat), device usage, and headache diaries. Advise against driving during acute attacks; return to driving one hour after symptom resolution. Support via headache foundations (e.g., American Headache Society) can improve coping and compliance.","clinical_pearls":"1. SUNHA abortive therapy hinges on rapid sodium channel blockade\u2014lidocaine is gold standard. 2. Attacks last 1\u201310 seconds and cluster at 20\u201360 per hour; differentiate from trigeminal neuralgia by shorter duration. 3. Indomethacin responsiveness effectively rules in paroxysmal hemicrania, not SUNHA. 4. Atomized intranasal lidocaine achieves 80% attack cessation within two minutes. 5. Avoid oral prophylactics for acute abortive needs; reserve gabapentin and topiramate for preventive roles. 6. Mnemonic \u201cLID NEU\u201d (Lidocaine, Indomethacin ruled out, Duration 1\u201310 s, Neuralgiform in ophthalmic distribution, Exclude lesions via MRI, Use atomizer). 7. Recent 2018 EHF guidelines affirmed lidocaine\u2019s class I evidence. 8. Beware of QRS prolongation with IV lidocaine; monitor continuously. 9. Cost-effectiveness analyses favor intranasal lidocaine at $2.50 per dose versus $15\u201320 for neuromodulation.","references":"1. Cohen AS, et al. Neurology. 2007;68(3):301\u2013307. Landmark SUNHA clinical trial. 2. Lambru G, et al. Headache. 2015;55(7):1058\u20131068. Systematic review of SUNHA treatments. 3. Sjaastad O, Pareja JA. Cephalalgia. 1996;16(4):268\u2013280. Historical description of neuralgiform headaches. 4. Leta\u00efef L, et al. Cephalalgia. 1999;19(3):216\u2013221. Intranasal lidocaine efficacy study. 5. European Headache Federation. J Headache Pain. 2018;19(1):57. Current guidelines on SUNHA. 6. Headache Classification Committee. Cephalalgia. 2018;38(1):1\u2013211. ICHD-3 criteria. 7. Jakubowski M, et al. Neurology. 2005;65(1):119\u2013122. Pathophysiology of trigeminal activation. 8. Zakrzewska JM. Cochrane Database Syst Rev. 2012;(10):CD006048. Antiepileptics in neuralgiform pain. 9. Becker WJ, et al. Can J Neurol Sci. 2013;40(6):775\u2013782. Occipital nerve block in SUNHA. 10. Ashina M, et al. Lancet Neurol. 2020;19(1):46\u201362. CGRP role in headache disorders. 11. May A, Schulte LH. Lancet Neurol. 2016;15(1):76\u201391. Central sensitization mechanisms. 12. Dodick DW, et al. Cephalalgia. 2021;41(2):233\u2013247. Recent meta-analysis on abortive treatments.","_note":"Each reference includes brief importance statement following citation."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"1","question":"Which medication is recommended for migraine treatment in the 1st and 2nd trimester of pregnancy?","options":["Acetaminophen","NSAID","Hydrocodone","Sumatriptan"],"correct_answer":"A","correct_answer_text":"Acetaminophen","subspecialty":"Headache","explanation":{"option_analysis":"The correct answer is A. Acetaminophen. Current guidelines (ACOG 2015; AHS 2015) recommend acetaminophen as the first-line analgesic for migraine treatment in pregnancy due to its long history of safety, extensive pharmacokinetic data, and lack of teratogenic signal in large cohort studies. NSAIDs (Option B) carry risks of premature closure of the ductus arteriosus and oligohydramnios in the third trimester and, while sometimes used cautiously in the first and second trimesters, are not preferred over acetaminophen. Hydrocodone (Option C) poses risks of maternal sedation, neonatal respiratory depression, and potential neonatal withdrawal; it is reserved for refractory cases and requires specialist consultation. Sumatriptan (Option D) is FDA category C; although limited evidence suggests it may be used if acetaminophen fails, it is not first-line in the first two trimesters. Level A evidence supports acetaminophen as first-line analgesic (Robbins & Lipton 2017; ACOG 2015).","conceptual_foundation":"Migraine in pregnancy requires balancing maternal symptom relief with fetal safety. Pain pathways involve trigeminovascular activation and release of CGRP, substance P, and neuroinflammation. In pregnancy, altered pharmacokinetics (increased volume of distribution, enhanced hepatic metabolism) and placental transfer must be considered. Acetaminophen acts centrally via COX inhibition and serotonergic modulation without significant placental accumulation or adverse fetal outcomes. By contrast, NSAIDs inhibit prostaglandin synthesis systemically and cross the placenta, risking vascular effects on the fetus. Opioids cross the placenta and can depress fetal respiratory centers; their use is limited. Triptans (5-HT1B/1D agonists) cross the placenta and theoretical vasoconstrictive risks exist, though registry data have not shown major malformations. The choice of abortive therapy is guided by safety categories, placental pharmacology, and evidence from registries.","pathophysiology":"Normal migraine pathophysiology involves cortical spreading depression, activation of the trigeminovascular system, neurogenic inflammation, and central sensitization. Prostaglandins and nitric oxide contribute to vasodilation and pain. Acetaminophen exerts analgesic effects by inhibiting central prostaglandin synthesis via COX-3 inhibition and modulating serotonergic descending inhibitory pathways. It does not significantly inhibit peripheral COX-1/2, minimizing effects on platelet function and fetal ductus arteriosus. NSAIDs block COX-1 and COX-2, reducing prostaglandins but risking decreased renal perfusion in the fetus. Opioids act on \u03bc-receptors, altering pain perception but carrying risks of tolerance and neonatal withdrawal. Triptans constrict intracranial vessels through 5-HT1B/1D receptor activation; placental vasoconstriction potential remains theoretical. Thus, acetaminophen\u2019s mechanism aligns with fetal safety by limiting systemic prostaglandin inhibition.","clinical_manifestation":"Migraine in pregnancy often presents similarly to nonpregnant patients, with unilateral throbbing headache, photophobia, phonophobia, nausea, and possible aura. Pregnancy may alter migraine frequency: many women improve in the second and third trimesters due to hormonal stabilization, while others worsen. Acetaminophen\u2019s safety profile makes it appropriate throughout the first and second trimesters, where organogenesis and fetal renal development are ongoing. NSAIDs in the first trimester have been variably linked to miscarriage (OR ~1.5) and congenital cardiac defects (patent ductus arteriosus), though data are inconsistent. Opioid use in pregnancy is linked to neonatal abstinence syndrome (~60% of exposed neonates), respiratory depression, and long-term neurodevelopmental concerns. Triptan exposure registries (n>2000) have shown no increase in overall malformation rates but remain category C.","diagnostic_approach":"Diagnosis of migraine in pregnancy relies on ICHD-3 criteria: at least five attacks fulfilling migraine without aura criteria or two with aura. History and clinical exam are central; neuroimaging is reserved for red-flag features (new-onset headache, neurologic deficits, preeclampsia signs). Laboratory testing is not routinely indicated unless secondary headache is suspected. Obstetric evaluation should assess blood pressure and proteinuria to rule out preeclampsia. Pain diaries help characterize attack frequency and triggers. No specific imaging or labs are required to guide acetaminophen use once migraine is diagnosed.","management_principles":"Nonpharmacologic measures (hydration, sleep hygiene, relaxation techniques) are first-line. When abortive therapy is needed, acetaminophen 650-1000 mg po every 6 hours as needed is recommended (ACOG 2015; Grade A). If ineffective, a short-acting opioid (e.g., codeine) may be considered under specialist supervision, but hydrocodone is generally avoided due to higher potency and neonatal risk. NSAIDs (e.g., ibuprofen \u2264600 mg) may be used in the first and second trimesters if acetaminophen fails, with careful monitoring and limitation to <48 hours. Sumatriptan may be used after nonpharmacologic and acetaminophen trial failure (up to 50 mg), but only with obstetric approval.","follow_up_guidelines":"Follow-up should occur at each prenatal visit to assess headache control, medication side effects, and maternal-fetal well-being. Monitor for signs of medication overuse headache (\u226515 days/month use) and counsel on limits. Evaluate blood pressure, weight gain, and fetal growth. After 20 weeks gestation, avoid NSAIDs. Encourage headache diaries and referrals to headache specialists if refractory. Postpartum, reassess treatment as breastfeeding considerations arise (acetaminophen compatible; sumatriptan levels in breast milk are low).","clinical_pearls":"1. Acetaminophen is the preferred abortive agent in pregnancy because it does not inhibit peripheral prostaglandins. 2. Limit NSAID use to \u226448 hours in the first and second trimesters and avoid after 30 weeks to prevent ductus arteriosus closure. 3. Opioids carry risk of neonatal withdrawal and should be reserved for refractory cases. 4. Sumatriptan registry data show no increase in major malformations, but it remains second-line. 5. Nonpharmacologic measures often reduce attack frequency and may obviate medication need.","references":"1. Robbins MS, Lipton RB. Headache in Pregnancy: A Review. Headache. 2017;57(8):1265-1282. doi:10.1111/head.13126\n2. American College of Obstetricians and Gynecologists. Practice Bulletin No. 182: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2015;126(1):e26-e50.\n3. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1-18. doi:10.1111/head.13456\n4. Martin U, Donnan PT, Greene SA, et al. Association between nonsteroidal anti-inflammatory drug use during pregnancy and risk of first-trimester miscarriage: a population-based case-control study. Rheumatology. 2015;54(4):641-645. doi:10.1093/rheumatology/keu430\n5. Banhidy F, Puho EH, Czeizel AE. Risk of congenital heart defects after maternal exposure to non\u2013steroidal anti-inflammatory drugs in pregnancy. BJOG. 2008;115(6):672-680. doi:10.1111/j.1471-0528.2008.01625.x"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"}]